NCT03221907

Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain

A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 352 (actual)
• Sponsor: Daewon Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain

Conditions

• Pain of Mononeuropathy

Interventions

Type	Name	Description
DRUG	GLA5PR GLARS-NF1	Pregabalin tablet
DRUG	GLA5PR GLARS-NF1 placebo	tablet manufactured to mimic GLA5PR GLARS-NF1
DRUG	Pregabalin	Pregabalin capsule
DRUG	Pregabalin placebo	tablet manufactured to mimic pregabalin capsule

Timeline

• Start date: 2016-04-11
• Primary completion: 2019-01-08
• Completion: 2019-01-08
• First posted: 2017-07-19
• Last updated: 2019-03-19

Locations

1 site across 1 country: South Korea